MITO28MaNGOov4: Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Sponsor

National Cancer Institute, Naples (Other)

Overall Status

Recruiting

CT.gov ID

NCT03410784

Collaborator

Mario Negri Institute for Pharmacological Research (Other)

Enrollment

Locations

Arm

Anticipated Duration (Months)

5.5

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy Paclitaxel and Carboplatin with Pembrolizumab in patients with advanced ovarian cancer. The main objective is to test whether the therapeutic intervention benefits the patient evaluating the number of subjects who are progression-free after 18 months from the beginning of the first line treatment.

Condition or Disease	Intervention/Treatment	Phase
Ovarian Cancer	Drug: Pembrolizumab Drug: Paclitaxel Drug: Carboplatin	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

72 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Clinical Trial of Pembrolizumab in Combination With Carboplatin-paclitaxel in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer: MITO28/MANGO OV4 Study

Actual Study Start Date :

Apr 1, 2018

Anticipated Primary Completion Date :

Aug 1, 2021

Anticipated Study Completion Date :

Dec 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Other: First-line chemotherapy with pembrolizumab Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks for up to 22 cycles Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles	Drug: Pembrolizumab Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles Drug: Carboplatin Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles

Arm

Intervention/Treatment

Other: First-line chemotherapy with pembrolizumab

Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks for up to 22 cycles Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles

Drug: Pembrolizumab

Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles

Drug: Paclitaxel

Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles

Drug: Carboplatin

Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles

Outcome Measures

Primary Outcome Measures

Proportion of patients free from progression [18 months from beginning of first line treatment]

Secondary Outcome Measures

progression free survival [3 years]
overall survival [5 years]
number of patients with complete and partial responses [18 months]
worst grade toxicity per patient [evaluated every 3 weeks up to 18 months]
according to Common Toxicity Criteria for Adverse Events v. 4.03
changes in patient-reported outcome (PRO) scores of disease-related symptoms from baseline [up to 18 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

In order to be eligible for participation in this trial, the subject must:

Have a histologically confirmed diagnosis of advanced (FIGO stage IIIB, IIIC, IV) epithelial ovarian, primary peritoneal or fallopian tube cancer.
Have evidence of residual tumor after debulking surgery OR be non-eligible neither for primary surgery nor for neoadjuvant chemotherapy followed by interval debulking surgery
Be willing and able to provide written informed consent/assent for the trial.
Be at least 18 years of age on day of signing informed consent.
Have measurable disease based on RECIST 1.1.
Have tumor samples available for biomarker analysis.
Have a performance status of 0 or 1 on the ECOG Performance Scale.
Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
Must be not eligible to receive Bevacizumab in combination with carboplatin and paclitaxel, due to contraindication, patient refusal or investigator choice
Demonstrate adequate organ function

Exclusion Criteria:

The subject must be excluded from participating in the trial if the subject:

Is currently participating and receiving study therapy or has participated in a study of an investigational agent or investigational device and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
Has a known history of active TB (Bacillus Tuberculosis)
Hypersensitivity to Pembrolizumab or any of its excipients.
Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (Grade 0 or 1 at baseline) from adverse events due to agents administered more than 4 weeks earlier.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (Grade 0 or 1 at baseline) from adverse events due to a previously administered agent.

Note: Subjects with Grade 1 or 2 neuropathy are an exception to this criterion and may qualify for the study.

Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 28 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
Has an active infection requiring systemic therapy.
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or other co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137) or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Contacts and Locations

Locations

	Site	City	Country
1	Ospedale Generale Regionale "F. Miulli "	Acquaviva delle Fonti	Italy
2	Istituto Tumori Giovanni Paolo II	Bari	Italy
3	Spedali Civili - Università di Brescia	Brescia	Italy
4	Ospedale Senatore Antonio Perrino	Brindisi	Italy
5	Fondazione del Piemonte per l'Oncologia	Candiolo	Italy
6	Istituto Romagnolo per lo Studio e la Cura dei Tumori	Meldola	Italy
7	Istituto Nazionale Tumori	MIlano	Italy
8	AOU Policlinico Federico II	Napoli	Italy
9	AOU Università degli studi della Campania "Luigi Vanvitelli"	Napoli	Italy
10	Istituto Nazionale dei Tumori	Napoli	Italy
11	Ospedale Silvestrini	Perugia	Italy
12	Ospedale S. Giovanni Calibita Fatebenefratelli	Roma	Italy
13	Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore	Roma	Italy

Sponsors and Collaborators

National Cancer Institute, Naples
Mario Negri Institute for Pharmacological Research

Investigators

Principal Investigator: Sandro Pignata, M.D., Ph.D., National Cancer Institute, Naples
Principal Investigator: Nicoletta Colombo, M.D., European Institute of Oncology
Principal Investigator: Francesco Perrone, M.D., Ph.D., National Cancer Institute, Naples
Principal Investigator: Gennaro Daniele, M.D., Ph.D., National Cancer Institute, Naples
Principal Investigator: Ciro Gallo, M.D., University of Campania "Luigi Vanvitelli"